Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2015

01-08-2015 | Letter to the Editor

Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients

Authors: Mariana Ferreira Leal, Danielle Queiroz Calcagno, Janete Chung, Vanessa Morais de Freitas, Samia Demachki, Paulo Pimentel Assumpção, Roger Chammas, Rommel Rodríguez Burbano, Marília Cardoso Smith

Published in: Clinical and Experimental Medicine | Issue 3/2015

Login to get access

Abstract

Gastric cancer (GC) is the second highest cause of cancer mortality worldwide. However, nowadays, most of the studies aiming to understand the gastric carcinogenesis analyzed tumors of individuals from Asian population and, thus, may not reflect the distinct biological and clinical behaviors among GC processes. Since several membrane proteins have been implicated in carcinogenesis, we aimed to evaluate ANXA2 and GAL3 role in gastric tumors and GC cell lines of individuals from northern Brazil. The cellular localization of ANXA2 and GAL3 in the GC cell lines was evaluated by immunofluorescence. Gene expression was evaluated by real-time reverse-transcription PCR and protein expression by Western blot in gastric adenocarcinomas and non-neoplastic gastric samples, as well as in GC cell lines. ANXA2 and GAL3 were presented as dots in the plasma membrane and cytoplasm in ACP02 and ACP03 cell lines. ANXA2 mRNA expression was up-regulated in 32.14 % of gastric tumors compared to non-neoplastic tissues. ANXA2 up-regulation was associated with the metastasis process in vivo and with cell line invasive behavior. GAL3 protein expression was at least 1.5-fold reduced in 50 % of gastric tumors. The reduced GAL3 expression was associated with the presence of distant metastasis and with a higher invasive phenotype in vitro. Our study shows that ANXA2 and GAL3 deregulated expression was associated with an invasive phenotype in GC cell lines and may contribute to metastasis in GC patients. Therefore, these proteins may have potential prognostic relevance for GC of individuals from northern Brazil.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
4.
11.
go back to reference Guo T, Fan L, Ng WH, et al. Multidimensional identification of tissue biomarkers of gastric cancer. J Proteome Res. 2012;. doi:10.1021/pr300212g. Guo T, Fan L, Ng WH, et al. Multidimensional identification of tissue biomarkers of gastric cancer. J Proteome Res. 2012;. doi:10.​1021/​pr300212g.
15.
16.
go back to reference Emoto K, Sawada H, Yamada Y, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339–45.PubMed Emoto K, Sawada H, Yamada Y, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339–45.PubMed
22.
go back to reference Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307–12.PubMed Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002;9:1307–12.PubMed
23.
go back to reference Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000;21:258–66.CrossRefPubMed Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol. 2000;21:258–66.CrossRefPubMed
24.
go back to reference Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26:1369–76.PubMed Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26:1369–76.PubMed
25.
go back to reference Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999;27:362–7.CrossRefPubMed Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999;27:362–7.CrossRefPubMed
27.
go back to reference van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;30A:1096–9.CrossRefPubMed van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;30A:1096–9.CrossRefPubMed
28.
go back to reference Lotz MM, Andrews CW Jr, Korzelius CA, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 1993;90:3466–70.CrossRefPubMedPubMedCentral Lotz MM, Andrews CW Jr, Korzelius CA, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA. 1993;90:3466–70.CrossRefPubMedPubMedCentral
29.
go back to reference Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen–Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86:2353–63.CrossRefPubMed Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen–Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86:2353–63.CrossRefPubMed
31.
go back to reference de Oliveira JT, de Matos AJ, Gomes J, et al. Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology. 2010;20:1341–52. doi:10.1093/glycob/cwq103.CrossRefPubMed de Oliveira JT, de Matos AJ, Gomes J, et al. Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology. 2010;20:1341–52. doi:10.​1093/​glycob/​cwq103.CrossRefPubMed
Metadata
Title
Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients
Authors
Mariana Ferreira Leal
Danielle Queiroz Calcagno
Janete Chung
Vanessa Morais de Freitas
Samia Demachki
Paulo Pimentel Assumpção
Roger Chammas
Rommel Rodríguez Burbano
Marília Cardoso Smith
Publication date
01-08-2015
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 3/2015
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-014-0299-0

Other articles of this Issue 3/2015

Clinical and Experimental Medicine 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine